The Directorate General of Foreign Trade (DGFT), under the Ministry of Commerce & Industry, has issued Public Notice No. 46/2024-25-DGFT dated February 6, 2025, announcing amendments to Standard Input Output Norms (SION) A-222 for the export of Erythromycin Stearate Tablets. As per the revised norms, each 250 mg Erythromycin Stearate tablet must contain 334 mg of Erythromycin Stearate as an input. For other variants of the export product, input-output norms will be determined on a pro-rata basis. This amendment has been made under paragraphs 1.03 and 2.04 of the Foreign Trade Policy 2023 and is effective immediately. The update aims to regulate input usage and ensure compliance with export standards.
Government of India
Ministry of Commerce & Industry
Department of Commerce
Directorate General of Foreign Trade
Public Notice No. 46/2024-25-DGFT | Dated: 6th February, 2025
Subject: Amendments in Standard Input Output Norms (SION) A-222 for export of Erythromycin Stearate Tablet.
In exercise of the powers conferred under paragraphs 1.03 and 2.04 of the Foreign Trade Policy-2023 as amended from time to time, the Director General of Foreign Trade makes the following amendments in Standard Input Output Norms (SION) A-222 for export of Erythromycin Stearate Tablet.
| Export Product | Quantity | SI. No. | Import Item/s | Quantity |
| Erythromycin Stearate tablets-250 mg. (each tablet contains erythromycin stearate equivalent to 250 mg. of Erythromycin | 1 Number Tablet | 1 | Erythromycin Stearate | 334 mg. |
Note: For other variants of export items, norms may be worked out on a pro-rata basis.
Effect of the Public Notice: Standard Input Output Norm appearing under A-222 is amended as above with immediate effect.
(Santosh Kuffiar Sarangi)
Director General of Foreign Trade
Ex-officio Addl. Secretary to the Government of India .
e-mail: dgft@nic.in
(Issued from File No. 01/82/0017/ADZ-25/DES-III)
